Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
Upcoming Investor Events
Additionally, Evolent announced that its executive management team will participate in upcoming investor conferences.A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Presentation webcast times will be posted on the website as they become available.
Canaccord Genuity 44th Annual Growth Conference at the Intercontinental Boston in Boston, Massachusetts on August 13, 2025
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Contacts:investorrelations@evolent.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-to-release-second-quarter-2025-financial-results-on-thursday-august-7-2025-302503580.html
SOURCE Evolent Health, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT
Enovis Corporation (NYSE:ENOV) is one of the best undervalued medical device stocks to buy now. In a report released on July 8, Vijay Kumar from Evercore ISI maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $46.00. A patient recieving cold therapy treatment using the company's products. The company reported continued commercial momentum in fiscal Q1 2025 results, with net sales for the quarter reaching $559 million and reported an 8% growth on a reported basis and 9% rise on a comparable basis from the same quarter last year. Reconstructive sales for the quarter rose 11% year-over-year on a reported basis. Enovis Corporation's (NYSE:ENOV) fiscal Q1 2025 results show a rebound in growth in Recon, net sales for which grew 11% on a reported and comparable basis. The company also showed accelerating momentum in new product introductions and continued execution in P&R, reflecting a 5% growth on a reported basis and 7% on a comparable growth basis. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22 minutes ago
- Yahoo
Morgan Stanley's Wealth Management Adds $59 Billion In Net New Assets, AUM Grows To $1.71 Trillion
Morgan Stanley (NYSE:MS) reported a second-quarter 2025 earnings of $2.13, up from $1.82 a year ago and beating the consensus of $2.02. Net earnings increased to $3.54 billion from $3.08 billion. The U.S. bank reported revenue of $16.79 billion, up 12% year over year, beating the consensus of $16.11 billion. Morgan Stanley's provision for credit losses jumped to $196 million, primarily driven by growth in the corporate loan portfolio and secured lending facilities, and the impact of a moderately weaker macroeconomic firm's expense efficiency ratio was 71% compared to 72% a year ago. Morgan Stanley's second-quarter Return on Tangible Common Equity was 18.2%, compared to 17.5% a year ago. Institutional Securities reported net revenues of $7.6 billion, propelled by View more earnings on MS Markets businesses on higher client activity, with notable strength in Equity. Investment Management results reflect net revenues of $1.6 billion, primarily driven by asset management fees on higher average assets under management (AUM) of $1.71 trillion (up 13%). The quarter included positive long-term net flows of $11 billion. Wealth management delivered net revenues of $7.76 billion on higher asset management revenues, compared to $6.79 billion a year ago. The business demonstrated continued strength with net new assets of $59 billion and fee-based asset flows of $43 billion for the quarter. Equity net revenues increased 23% to $3.72 billion, reflecting increases from a year ago across business lines and regions on higher client activity, with robust results in prime brokerage. Fixed Income net revenues increased 9% from a year ago to $2.18 billion, primarily driven by higher results in macro products and higher client activity in a more volatile market environment. Lower results in commodities partially offset the increase. On Wednesday, Chairman and Chief Executive Officer Ted Pick said, "Morgan Stanley delivered another strong quarter. Six sequential quarters of consistent higher levels of performance in different market environments. Institutional Securities saw strength and balance across businesses and geographies." Price Action: MS stock is down 1.38% at $139.64 during the premarket session at the last check Wednesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Morgan Stanley's Wealth Management Adds $59 Billion In Net New Assets, AUM Grows To $1.71 Trillion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Avanos Medical (AVNS) Appoints Camille Chang Gilmore as SVP and Chief Human Resources Officer
Avanos Medical, Inc. (NYSE:AVNS) is one of the best undervalued medical device stocks to buy now. On June 9, Avanos Medical, Inc. (NYSE:AVNS) announced the appointment of Camille Chang Gilmore as senior vice president, SVP, and chief human resources officer. A medical professional using a chronic care product in a hospital. The transition would put her in charge of all aspects of the company's people strategy, including workforce planning, talent acquisition and development, and leadership development and employee experience. Avanos Medical, Inc. (NYSE:AVNS) announced $167.5 million in total net sales in fiscal Q1 2025, a 0.8% growth from the same period last year. Net income for the quarter reached $6.6 million, compared to net income from continuing operations of $0.5 million a year ago. Adjusted net income also rose to $12.0 million, compared to $10.1 million in the same period last year. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company that delivers medical device solutions and products to healthcare providers and patients. While we acknowledge the potential of AVNS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
